INTERSTITIAL LUNG DISEASE (G TINO, SECTION EDITOR)
Connective tissue disease-associated interstitial lung disease:
Markus Gutsche & Glenn D. Rosen & Jeffrey J. Swigris
Published online: 21 September 2012
# Springer Science+Business Media, LLC 2012
Abstract Interstitial lung disease (ILD) is commonly en-
countered in patients with connective tissue diseases (CTD).
Besides the lung parenchyma, the airways, pulmonary vascu-
lature and structures of the chest wall may all be involved,
depending on the type of CTD. As a result of this so-called
multi-compartment involvement, airflow limitation, pulmo-
nary hypertension, vasculitis and extrapulmonary restriction
can occur alongside fibro-inflammatory parenchymal abnor-
malities in CTD. Rheumatoid arthritis (RA), systemic sclero-
sis (SSc), polymyositis/dermatomyositis (PM/DM), Sjögren’s
syndrome (SjS), systemic lupus erythematosus (SLE), and
undifferentiated connective tissue disease (UCTD), as well
as mixed connective tissue disease (MCTD), can all be asso-
ciated with the development of ILD. Nonspecific interstitial
pneumonia (NSIP) is the most commonly observed histopath-
ological pattern in CTD-ILD, but other patterns, including
usual interstitial pneumonia (UIP), organizing pneumonia
(OP), diffuse alveolar damage (DAD) and lymphocytic inter-
stitial pneumonia (LIP), may occur. Although the majority of
ILD, a small yet significant group exhibits a more severe and
progressive course. Randomized placebo-controlled trials
been conducted only in SSc-associated ILD. However, clini-
cal experience suggests that a handful of immunosuppressive
medications are potentially effective in a sizeable portion of
patients with ILD caused by other CTDs. In this manuscript,
we review the clinical characteristics and management of the
most common CTD-ILDs.
Lung involvement is common in connective tissue diseases
(CTDs) and can lead to significant morbidity and shortened
survival. Depending on the underlying CTD, various thoracic
compartments can be involved simultaneously; although, for
this review, we will focus on the parenchymal changes of
CTD-associated interstitial lung disease (CTD-ILD). Most
CTD-ILD presents with a dry cough, gradually progressive
dyspnea and a restrictive ventilatory defect on pulmonary
function tests (PFTs). Many patients diagnosed with CTD-
ILD have a classifiable CTD at the time ILD is recognized;
however, in up to 25 % of cases, a constellation of clinical and
serological findings suggest, but are not entirely diagnostic of,
a classifiable CTD. Patients in such a scenario have been
labeled with “undifferentiated” CTD (UCTD), lung-dominant
CTD and autoimmune-featured ILD by various investigators
[1••, 2]. Lung disease can also predate extrapulmonary CTD
manifestations by several years, thus making the distinction
between CTD-ILD and an idiopathic interstitial pneumonia
(IIP) difficult . Below, we provide a general description of
the physiological, histological and radiological findings and
management features of CTD-ILD and proceed to highlight
of each individual CTD.
M. Gutsche:G. D. Rosen
Interstitial Lung Disease Program, Division of Pulmonary
and Critical Care Medicine, Stanford University,
Stanford, CA, USA
J. J. Swigris (*)
Autoimmune Lung Center and Interstitial Lung Disease Program,
National Jewish Health,
1400 Jackson Street,
Denver, CO 80206, USA
Curr Respir Care Rep (2012) 1:224–232
Clinical features of CTD-ILD
Pulmonary function testing (PFT) The classic PFT pattern
observed in CTD-ILD is a restrictive ventilatory defect and
reduced diffusion capacity (DLco). However, when other
thoracic compartments such as airways, vasculature or chest
wall are involved (as may occur in CTD), clinicians should
be aware that a different constellation of PFT-abnormalities
can arise. For example, a disproportionate reduction in
DLco may signify ILD with coexistent emphysema or pul-
monary hypertension [4••], or a significant reduction in lung
volumes with relatively preserved DLco should raise suspi-
cion for extrapulmonary restriction (e.g., chest wall skin
thickening, respiratory muscle weakness or kyphoscoliosis).
Histopathological patterns Except for rheumatoid arthritis
(RA), in which usual interstitial pneumonia (UIP)-pattern
pathology is more common, the nonspecific interstitial
pneumonia (NSIP) pattern of lung injury is most common
across all CTD-ILD [5, 6•] Compared with cases in which
UIP-pattern injury is idiopathic (i.e., idiopathic pulmonary
fibrosis [IPF]), CTD-associated UIP (CTD-UIP) has fewer
fibroblastic foci, smaller honeycomb cysts, a greater number
of germinal centers and more inflammation . Although
results are conflicting, some studies suggest patients with
CTD-UIP have a better prognosis than IPF-patients. Also a
matter of debate, some studies suggest no difference in
prognosis between CTD-UIP and CTD-NSIP, contrasting
with what is known about the difference in prognosis be-
tween idiopathic NSIP and IPF [6•, 8, 9] Less commonly
encountered injury patterns of CTD-ILD include organizing
pneumonia (OP)—although OP not uncommonly occurs as
a secondary feature in patients with CTD—diffuse alveolar
damage (DAD), lymphocytic interstitial pneumonia (LIP)
and desquamative interstitial pneumonia (DIP).
Because of conflicting study results, many clinicians are
uncertain about the utility of surgical lung biopsy (SLBx) in
their patients with CTD-ILD. On the one hand, many clini-
cians believe that, among patients with CTD-ILD, UIP-
pattern histology confers a worse prognosis than NSIP-
pattern histology. Those in this camp would have their
CTD-ILD patients undergo SLBx, because the results could
better define disease trajectory. On the other hand, clinicians
not using SLBx in their patients with CTD-ILD are either
unconvinced that the histological pattern trumps pulmonary
physiology in determining prognosis, or more likely, do not
expect the results to change management: they plan to treat
(or perhaps already are treating) with immunosuppressive
medications, and the SLBx pattern would not affect their
choice of therapeutic agent or anticipated duration of thera-
py. When an etiology for the ILD other than CTD (e.g.
hypersensitivity pneumonitis) is seriously considered, or
when imaging features suggest malignancy or infection
(e.g. progressive nodules, cavitation, consolidation, pleural
thickening or effusion), there is greater consensus about the
utility of SLBx in this patient population.
High-resolutioncomputer tomography (HRCT) findings Most
parenchymal abnormalities in CTD-ILD are easily appreci-
ated with HRCT and commonly described using terminolo-
gy applied to IIPs (Figs. 1 and 2). While each CTD
demonstrates a predilection for a certain pattern of paren-
chymal involvement, significant overlap exists (Table 1)
[10••, 11]. Overall, a radiographic NSIP-pattern is found most
commonly in CTD-ILDs, and is characterized by intralobular
and interlobular reticular opacities in a predominantly sub-
pleural and basilar distribution. Ground-glass opacities are
usually considered to represent a higher degree of cellularity
and suggest the disease is potentially more responsive to
treatment, although in some cases this is not true. Subpleural
sparing—an opacity-free, thin rim of parenchyma directly
adjacent to the pleura in the posterior zones of the lung
bases—hints at an underlying NSIP-pattern of lung injury
and argues against the UIP-pattern. Reticulation, traction
bronchiectasis and honeycombing reflect fibrotic changes
and more advanced ILD. Abnormalities in other thoracic
structures (e.g., esophageal or pulmonary artery dilatation)—
hinting at the presence of multi-compartment involvement—
should raise suspicion for the presence of a CTD [12••, 13••].
Serological studies Serum auto-antibodies will be explored
in the sections covering each of the CTDs below [13••].
General strategies in the management of CTD-ILD Not
every patient with CTD-ILD requires treatment; thus, it is
important to distinguish trivial disease (with low likelihood
for progression) from clinically significant ILD. HRCT and
PFTs are most helpful in objectively determining disease
severityand its courseovertime,but strongconsensus regard-
ing which patients to treat, when and for how long has not
been achieved for CTD-ILD. In our experience, patients with
disease extent <10 % on HRCT and/or forced vital capacity
Fig. 1 Slice from a HRCT scan from a 65-year-old man with rheuma-
toid arthritis. Note the honeycombing characteristic of a radiographic
Curr Respir Care Rep (2012) 1:224–232225
(FVC)>75 % and/or DLco>65 %, in the absence of respira-
tory symptoms, can be carefully monitored every 3–6 months
for evidence of progression. Since immunomodulatory med-
ications are associated with significant adverse effects, we
reserve treatment for those cases with severe, extensive or
progressive disease. Various regimens have been used to treat
CTD-ILD, but the only large-scale, randomized trials have
been conducted to examine the effectiveness of cyclophos-
phamide (or cyclophosphamide followed by azathioprine) in
patients with SSc-ILD [14, 15]. Data for other immunomod-
ulatory drugs (including azathioprine, mycophenolate mofetil
and tacrolimus) stem from case reports and observational case
series [16-18]. We typically evaluate the response to therapy
every three months. A favorable response may be defined as
improvement in symptoms and functional capacity, or disease
extent on HRCT or pulmonary physiology; however, in this
challenging spectrum of diseases, halting progression and
maintaining stability should also be considered a success. As
mentioned above, there are a number of questions that remain
ripe for investigation.
ILD in specific CTDs
Rheumatoid arthritis (RA) RA is the most common CTD
and is characterized by an erosive inflammatory polyarthr-
opathy with symmetrical arthritis and a range of pulmonary
manifestations. While RA occurs more commonly in
females (female to male ratio 3:1), RA-ILD is more frequent
in males. The prevalence of RA-ILD varies from 5–58 %,
depending on the case definition for ILD [19-21]. Smoking
is a risk factor for RA-ILD, and emerging data suggest that
cigarette smoke exerts its effects by promoting the citrulli-
nation of various proteins in the lung. In fact, theories have
arisen that seropositive RA “starts” in the lung [22, 23].
Severe ILD may occur when joint disease is mild or well
controlled with therapy—there appears to be no reliable
correlation between the extent or severity of the joint disease
and the development or progression of ILD in patients
RA-ILD manifests most commonly in the UIP-pattern,
and less commonly with NSIP-pattern injury. However,
clinicians caring for patients with RA must keep in mind
that medications used to treat extrapulmonary disease (e.g.,
methotrexate) can cause ILD and predispose to opportunis-
tic infections. Thus, a detailed drug history is crucial in all
patients with CTD-ILD. A temporal relationship between
drug initiation and symptom onset and then improvement
after withdrawal can point toward drug-induced lung dis-
ease. However, delayed reactions or continued progression
despite stopping the medication can occur, making the dif-
ferentiation between drug-induced ILD and worsening RA-
ILD challenging. In this situation, diagnostic BAL can help
to exclude infectious etiologies, while BAL-lymphocytosis
and/or eosinophilia with or without peripheral blood eosin-
ophilia can further support the diagnosis of drug-induced
ILD. Some of the most commonly prescribed medications
implicated in pulmonary toxicity include methotrexate,
leflunomide, gold salts, sulfasalazine, and anti-tumor necro-
sis factor (anti-TNF) antibodies [24-28] Ahelpfulonlinetool
listing all medications associated with pulmonary toxicity in
further detail can be found at pneumotox.com [29••]. We
toxicity in RA patients with pre-existing lung disease.
Due to the absence of randomized controlled trials, the
treatment of RA-ILD remains entirely empirical. High-dose
corticosteroids are often used in patients with potentially re-
versible patternssuchasOP or those withflares of RA-ILD.In
addition, cyclophosphamide, azathioprine, cyclosporine or
mycophenolate have been used as steroid sparing agents or
in steroid-refractory cases [17, 18, 30-32]. In our experience,
biologic agents control the joint disease very well, but have
minimal effect on ILD. Lung transplantation is offered by
certain centers to RA-ILD patients with limited joint disease
and relatively preserved functional status.
Fig. 2 Coronal view slice from a HRCT scan from a 58-year-old
woman with dermatomyositis. Notice the ground-glass opacities and
traction bronchiolectasis characteristic of mixed cellular and fibrotic
Table 1 Radiological pattern in CTD-ILD [10, 11]
NSIP UIPOPPHDAD LIP Hemorrhage Airways
PM/DM ++++ +
The number of ‘+’ signs indicates the frequency of observed injury
pattern, i.e., ++++ 0 very common or clinically prominent manifestation,
+ 0 less common, empty cells 0 rare or not described in this disease;
RA0rheumatoid arthritis; SSc0systemic sclerosis; PM/DM0polymyosi-
tis/dermatomyositis; SjS0Sjögren’s syndrome; MCTD0mixed-connec-
tive tissue disease; SLE0systemic lupus erythematosus
226Curr Respir Care Rep (2012) 1:224–232
Systemic sclerosis Systemic sclerosis is the CTD with the
largest percentage of patients afflicted with ILD (40–80 %,
depending on method of ascertainment). Along with pulmo-
nary hypertension (PH), ILD is a major cause of death in this
disease [33•, 34]. The frequency of ILD depends on ethnicity,
autoantibody pattern, and less so on the extent of skin disease.
Most patients with SSc have high titers of antinuclear anti-
bodies (ANA)—most often in a nucleolar pattern. Three anti-
bodies with the highest specificity for SSc include
antibodies against anti-RNA polymerase III (Pol3), anti-
centromere antibodies (ACA) and antibodies against
topoisomerase (anti-Scl70). Anti-Scl70 antibodies are
strongly associated with ILD . Although ACA are
protective from significant ILD, patients with ACA carry a
high risk for the development of PH later in the course of the
disease [35•]. The Pol3 antibody is seen with diffuse skin
disease and renal crisis, but is rarely associated with signifi-
cant lung fibrosis [35•].
The majority of patients with SSc-ILD have NSIP-pattern
injury . Less commonly, a UIP-pattern is observed, and
other histophatological patterns (e.g., OP or DAD) are very
rare. As with other CTD-ILD patients, a subset with SSc-ILD
is believed not to require treatment. Some experts adhere to
using a staging system to help determine which SSc-
ILD patients to treat with immunomodulatory therapy:
Goh and colleagues observed that patients with lung
involvement greater than 20 % on HRCT and a FVC<
70 % of predicted were most likely to progress without
therapy . Such patients with more severe disease are
often treated aggressively.
Two randomized placebo controlled trials, the Scleroder-
ma Lung Study (SLS) and the Fibrosing Alveolitis Sclero-
derma Trial (FAST), evaluated cyclophosphamide (given
orally at 2 mg/kg for one year in SLS, and intravenously
at a dose of 600 mg/m2 monthly for six months, followed by
oral azathioprine for the following six months in FAST) for
SSc-ILD [14, 15]. Results from both studies demonstrated a
slower decline in FVC in the cyclophosphamide group
compared with placebo. Intravenous administration of cy-
clophosphamide was associated with a lower rate of gonadal
failure, severe infections and bone marrow toxicity com-
pared to oral medication, presumably due to higher cumu-
lative dose achieved with daily oral medication . Six
months after discontinuation of immunosuppression, the
improvements in FVC waned to baseline, suggesting pro-
longed immunomodulatory therapy may be required to
maintain stability of lung function .
Whether there is a causal relationship between ILD and
esophageal dysmotility/gastroesophageal reflux disease
(GERD)/microaspiration is unclear, but we believe aggres-
sive treatment of these abnormalities in patients with SSc-
ILD (and any other ILD patient with them) is warranted. Co-
management with gastroenterology can be helpful.
Polymyositis and dermatomyositis Both polymyositis (PM)
and dermatomyositis (DM) share the diagnostic criteria of
symmetrical proximal muscle weakness, raised serum mus-
cle enzymes, and muscle biopsy and electromyography
results consistent with myositis. In addition, DM requires
the presence of certain skin manifestations (e.g., heliotrope
rash and Gottron’s sign) to fulfill diagnostic criteria [40,
41•]. In amyopathic DM, classical skin findings of DM are
present without muscle involvement . Overall, pulmo-
nary disease is present in one-third to two-thirds of patients
and is a significant cause of mortality in PM/DM [43•].
In patients with clinically significant disease, two main
types of clinical presentations have been observed. The first
is characterized by subacute onset of dyspnea and wide-
spread basilar predominant ground-glass opacities and con-
solidation against a background of reticulation with traction
bronchiectasis on CT [44•]. Many patients presenting this
way progress significantly over a few weeks to months and
are refractory to therapy. Histopathologically, a DAD pat-
tern atop both OP and NSIP has been described in this
setting [45, 46]. The other form of presentation is more
common and involves an insidious onset and slowly pro-
gressive dyspnea. A combined pattern of NSIP and OP are
observed on HRCT and in histopathological specimens
[47-49]. Other patients with PM/DM can present with a
UIP-pattern of lung injury.
As with most CTDs, lung involvement in PM/DM may
occur before, after or at the same time of the development of
extrapulmonary manifestations [50, 51]. Risk factors for the
development of PM/DM-ILD include a higher age (>45),
joint involvement [51, 52], and in particular, the presence of
aminoacyl-tRNA synthetase (i.e., anti-synthetase or AS)
antibodies. The most commonly identified AS antibody is
directed against anti-histidyl-tRNA synthetase (anti-Jo1)
and is present in 25–40 % of all patients with PM/DM
[53•, 54, 55] and in 30–75 % of those cases with ILD [49,
52, 56-58]. Other less commonly found antibodies include
anti-PL-7, -PL-12, -OJ, -EJ, -KS and -Zo [51, 55, 59]. The
combination of arthritis, myositis, anti-synthetase antibodies
and ILD constitutes the anti-synthetase syndrome. Ray-
naud’s phenomenon, “mechanic’s hands” (dry, rough, fis-
sured skin of the hands, particularly on the thenar side of the
index finger and the finger tips) and fever, while not part of
the diagnostic criteria of anti-synthetase syndrome, are other
findings frequently encountered . It is not entirely clear
whether AS antibodies are pathogenic or merely disease
markers. In addition, it is unknown whether the different
AS antibodies portend different clinical phenotypes.
As with most other CTDs, no definitive recommenda-
tions for the treatment of PM/DM-associated ILD exist due
to the lack of randomized clinical trials. High-dose oral
prednisone is often used as first-line therapy in PM/DM-
associated ILD. In the US, azathioprine and mycophenolate
Curr Respir Care Rep (2012) 1:224–232227
are the most frequently used immunomodulatory agents for
PM/DM-ILD; however, there are case reports and case
series suggesting a role for the calcineurin antagonists [60,
61]. In severe, rapidly progressive disease, intravenous cy-
clophosphamide in conjunction with high-dose methylpred-
nisone has been used [62, 63]. Rituximab has been tried in
patients who failed to respond to conventional immunosup-
pressive regimens or who presented with rapidly progres-
sive DAD [64, 65]. In addition to treating refractory
myositis, intravenous immunoglobulins have been used
with some success to treat rapidly progressive ILD . In
PM/DM, the risk of malignancy is increased and screening
for occult neoplasm should be considered, particularly in
patient without AS antibodies.
Sjögren’s syndrome In 1933 Sj gren introduced the term
“keratoconjunctivitis sicca”, also referred to as “sicca com-
plex” to describe a syndrome characterized by dry eyes and
dry mouth . Sj gren’s syndrome (SjS) is a chronic in-
flammatory condition characterized by lymphocytic infiltra-
tion of exocrine glands (including salivary and lacrimal
glands), and other structures, including the lungs. It can
occur either in isolation, when it is referred to as primary
SjS, or as a secondary phenomenon in the setting of another
established CTD, in which case it is termed secondary SjS
[68•]. The primary form displays more severe exocrine
dysfunction, including renal tubular disorder, neurological
involvement and vascular disorders (Raynaud’s phenome-
non and vasculitis) . In the absence of a salivary gland
biopsy demonstrating focal lymphocytic sialoadenitis, the
presence of “keratoconjunctivitis sicca” and anti-nuclear anti-
bodies against ribonucleoproteins Ro/SSA and La/SSB is
required to fulfill diagnostic criteria in both primary and
secondary SjS . Polyclonal hypergammaglobulinemia,
elevated sedimentation rate and other autoimmune antibodies
(e.g., rheumatoid factor) can be found with varying frequency
in SjS and are nonspecific [70, 71]. Patients with SjS are at
increased risk for pulmonary and other lymphomas [72•, 73].
Although restriction and reduced DLco have been found
in 17–37.5 % of patients with SjS, clinically significant ILD
is rare, and in most cases SjS-ILD follows a mild and self-
limited course [74, 75]. Respiratory symptoms mostly relate
to dry mucous membranes predisposing patients with SjS to
hoarseness and dry cough (due to xerotrachea). Patients with
SjS are at increased risk of respiratory tract infections, due
to impaired immune function of the mucosal barrier lining
the airway epithelium. Exertional dyspnea is reported by
some patients [75, 76]. Pleuritis, PAH, middle lobe syn-
drome and shrinking lung syndrome have been described
in SjS rarely [77•, 78-80].
Authors of older series reported LIP as the most common
histopathological pattern in patients with SjS, but more
recent studies have revealed a higher frequency of NSIP-
pattern injury in this disease [81•, 82]. This finding is likely
based on the reclassification of many cases as cellular NSIP,
which in the past would have been interpreted as LIP .
Other less commonly observed patterns include OP and UIP.
In patients with SjS-ILD, HRCT and histopathological find-
ings correlate well with each other, so SLBx is usually not
recommended [82, 84, 85]. However, radiographic features
suggestive of lymphoma (see below) require thorough in-
vestigation [86•]. Ground-glass opacities and thin-walled
cysts in a peri-bronchovascular distribution can occur with
LIP. Centrilobular nodules are noted with LIP or lympho-
cytic bronchiolitis. Pulmonary lymphoma accounts for ap-
proximately 20 % of all SjS-associated lymphomas [73, 74].
Both LIP and pulmonary lymphoma have overlapping fea-
tures, including ground-glass opacification, small nodules
and hilar-mediastinal lymphadenopathy. Consolidation,
large nodules measuring more than 10 mm, as well as
pleural effusions, are more common in lymphoma, whereas
cysts are more frequently observed in LIP .
Unclassifiable connective tissue disease
A large minority of patients with ILD do not fulfill the
diagnostic criteria for any specific CTD, but display features
including positive serologies and systemic extrapulmonary
manifestations that are reminiscent of an underlying auto-
immune disease. Such patients have been labeled as having
an “autoimmune flavor” . Over the course of follow-up,
a number of these patients go on to develop clinical and
serological characteristics that fulfill diagnostic criteria for a
specific CTD [88•]. Ongoing investigations aim to deter-
mine how best to follow, treat and conduct research in this
interesting population. Such patients are different from those
with anti-U1 RNP antibodies and features of more than one
specific CTD who have mixed connective tissue disease
(MCTD)—a specific CTD [89•]. While a large number of
patients with MCTD have pulmonary involvement, most
have relatively mild disease, and many are asymptomatic
. Pleural effusions, ILD consistent with NSIP and some-
times UIP, and PAH, either as a result of CTD-ILD or in
isolation, have all been described in MCTD [91•, 92].
Systemic lupus erythematosus SLE is a multisystem disor-
der afflicting joints, skin, kidneys, central nervous system,
and serosal surfaces of internal organs including heart and
lungs. The disease is more prevalent in women of reproduc-
tive age and African Americans . Almost all patients are
anti-nuclear antibody (ANA) positive [94, 95]. Four or more
criteria are required to establish the diagnosis [96•]. Inter-
estingly, these criteria do not include any pulmonary mani-
festations, except for pleuritis. Although respiratory
symptoms associated with SLE are often absent, abnormal
228 Curr Respir Care Rep (2012) 1:224–232
PFT and HRCT findings are common, and the prognosis is
significantly worse in patients experiencing pulmonary
complications [97, 98•, 99, 100].
While trivial lung disease is present in one third of
patients, clinically significant disease afflicts only 3–8 %
of the lupus population [101, 102]. In some cases, acute
lupus pneumonitis (ALP) with a DAD-pattern heralds the
development of ILD . Similar to most other CTD-
ILDs, NSIP is the most commonly observed histopatholog-
ical pattern, but LIP, OP and UIP have all been described
[98•, 104-106]. Diffuse alveolar hemorrhage (DAH) and
ALP are characterized by acute onset of dyspnea with fever,
cough and in the case of DAH, sometimes hemoptysis. A
sudden decrease in hemoglobin is highly suggestive of
DAH [99, 104, 107, 108]. Approximately one-half of
patients with DAH require mechanical ventilation. An in-
creasingly bloody return on BAL is diagnostic and sup-
ported by high counts of red blood cells and hemosiderin-
laden macrophages on the differential cell count. A neutro-
philic capillaritis and alveoli filled with red blood cells are
seen on histopathology of lung tissue from patients with
DAH . In ALP, the histopathological picture resembles
DAD, but without hemorrhage or capillaritis . Both
ALP and DAH present with diffuse, bilateral ground-glass
opacities on HRCT. In this setting pulmonary edema, drug
reactions as well as infection all need to be excluded.
Due to the high incidence of infections in SLE, broad-
spectrum antibiotic therapy should be started empirically with-
out delay, while infectious etiologies are excluded and before
aggressive immunosuppression is initiated. DAH and ALP
carry a mortality rate of 50 % [104, 109]. In patients requiring
mechanical ventilation, a lung protective strategy with low
tidal volumes should be used. We recommend high-dose in-
travenous methylprednisone (1 g daily for 72 hours), followed
mide. In refractory cases of DAH or ALP, plasmapheresis and
intravenous immunoglobulins have been described [99, 104].
Success with rituximab has also been reported .
CTD-ILD comprises a heterogeneous group of disorders
marked by varying degrees of fibrosis and/or inflammation
within the lung parenchyma. ILD is a potentially morbid and
life-threatening complication of any CTD, but it is most
commonly seen in patients with RA, SSc or PM/DM. A
large group of patients have features suggestive of CTD, but
cannot be classified according to currently available sys-
tems. How best to treat them—or other patients with CTD-
ILD—is based largely on experience and observational
studies. Future research is required to advance understand-
ing of the pathogenesis of CTD-ILD and to help determine
which patients require therapy, what drugs to use and how
long to use them.
Development Award from the NIH (K23 HL092227).
Dr. Swigris is supported in part by a Career
No potential conflicts of interest relevant to this article
Papers of particular interest, published recently, have been
• Of importance
•• Of major importance
1. •• Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM.
Connective tissue disease-associated interstitial lung disease: a call
for clarification. Chest. 2010;138(2):251–6. A synopsis and discus-
sion of “lung-dominant connective tissue diseases”, “autoimmune-
featured ILD” and “undifferentiated connective tissue diseases”
including a proposal for criteria to more accurately capture the
group of “lung-dominant CTDs”.
2. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung
disease: a distinct entity. Chest. 2011;140(5):1292–9.
3. Homma Y, Ohtsuka Y, Tanimura K, Kusaka H, Munakata M,
Kawakami Y, Ogasawara H. Can interstitial pneumonia as
the sole presentation of collagen vascular diseases be
differentiated from idiopathic interstitial pneumonia? Respiration.
4. •• Wells AU. Pulmonary function tests in connective tissue disease.
Semin Respir Crit Care Med. 2007;28:379–88. Excellent summary
on pulmonary function test patterns observed in CTD-ILD.
5. Lee H, Kim DS, Yoo B, Seo JB, Rho J, Colby TV, et al. Histopath-
ologic pattern and clinical features of rheumatoid arthritis-
associated interstitial lung disease. Chest. 2005;127:2019–27.
6. • Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan
R, et al. Rheumatoid arthritis-related lung diseases: CT findings.
Radiology. 2004;232:81–91. Description of characteristic HRCT-
patterns in patients with RA-related ILD.
7. Song JW, Do K, Kim M, Jang SJ, Colby TV, Kim DS.
Pathologic and radiologic differences between idiopathic
and collagen vascular disease-related usual interstitial pneu-
monia. Chest. 2009;136:23–30.
8. Park JH, Kim DS, Park I, Jang SJ, Kitaichi M, Nicholson AG, et
al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus
collagen vascular disease-related subtypes. Am J Respir Crit Care
9. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden
JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-
associated interstitial lung disease. Eur Respir J. 2010;35:1322–8.
10. •• King TE Jr, Kim EJ, Kinder BW. Connective tissue diseases.
In: King TE, Schwartz M, editors. Interstitial lung disease. 5th ed;
2011. Detailed review of connective tissue disease – related
interstitial lung diseases from standard reference textbook for
the interstitial lung diseases.
11. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases
associated with collagen vascular diseases: radiologic and histo-
pathologic findings. Radiographics. 2002;22:S151–65.
12. •• Hwang JH, Misumi S, Sahin H, et al. Computed tomographic
features of idiopathic fibrosing interstitial pneumonia: comparison
Curr Respir Care Rep (2012) 1:224–232 229
with pulmonary fibrosis related to collagen vascular disease.
J Comput Assist Tomogr. 2009;33:410–5. Comprehensive
reviews of radiologic and histopathologic features in CTD-
13. •• Lynch DA. Lung disease related to collagen vascular disease. J
Thoracic Imaging. 2009;24(4):299–309. Excellent overview of
radiologic, serologic and histopathologic patterns of lung injury
14. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst
DE, et al. Cyclophosphamide versus placebo in scleroderma lung
disease. N Engl J Med. 2006;354:2655–66.
15. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P,
Goh NSL, et al. A multicenter, prospective, randomized,
double-blind, placebo-controlled trial of and intravenous cy-
clophosphamide followed by oral azathioprine for the treat-
ment of pulmonary fibrosis in scleroderma. Arthritis Rheum.
16. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofe-
til in 10 patients with autoimmune-related interstitial lung disease
demonstrates promising effects. Am J Med Sci. 2009 May;337
17. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is
safe, well-tolerated, and preserves lung function in patients with
connective tissue disease-related interstitial lung disease. Chest.
18. Kobayashi A, Okamoto H. Treatment of interstitial lung diseases
associated with connective tissue diseases. Expert Rev Clin Phar-
19. Hyland RH, Gordon DA, Broder I, Davies GM, Russell ML,
Hutcheon MA, et al. A systematic controlled study of
pulmonary abnormalities in rheumatoid arthritis. J Rheumatol.
20. Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary
involvement in rheumatoid arthritis and its relationship to some
characteristics of the patients. A radiological and clinical study.
Scand J Rheumatol. 1982;11:217–24.
21. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D,
Lake FR. Interstitial lung disease in recent onset rheumatoid
arthritis. Am J Respir Crit Care Med. 1997;156:528–35.
22. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW,
Schwartz DA. Cigarette smoking and rheumatoid arthritis sever-
ity. Ann Rheum Dis. 1997;56:463–9.
23. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthri-
tis: identification, evaluation, and future directions for investiga-
tion. Rheum Dis Clin North Am. 2010;36(2):213–41.
24. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms
AM, van de Putte LB. Methotrexate-related pulmonary compli-
cations in rheumatoid arthritis. Ann Rheum Dis. 1994;53:434–9.
25. Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et
al. Leflunomide-related lung injury in patients with rheumatoid
arthritis: imaging features. Mod Rheumatol. 2005;15:173–9.
26. Scott DL, Bradby GV, Aitman TJ, Zaphiropoulos GC, Hawkins
CF. Relationship of gold and penicillamine therapy to diffuse
interstitial lung disease. Ann Rheum Dis. 1981;40:136–41.
27. Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and
lung toxicity. Eur Respir J. 2002;19:756–64.
28. Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW. Pul-
monary complications of tumor necrosis factor-targeted therapy.
Respir Med. 2009;103:661–9.
29. •• pneumotox.com – Foucher P, Camus P. The drug-induced lung
diseases. Very useful online tool that allows searches for individ-
ual medications listing all respective drug-induced pulmonary
complications described in the literature.
30. Abel T, Andrews BS, Cunningham PH, et al. Rheumatoid vasculi-
tis: Effect of cyclophosphamide on the clinical course and levels of
circulating immune complexes. Ann Intern Med. 1980;93:407–13.
31. Chang HK, Park W, Ryu DS. Successful treatment of progressive
rheumatoid interstitial lung disease with cyclosporine: A case
report. J Korean Med Sci. 2002;17:270–3.
32. Scott DGI, Bacon PA. Resonse to methotrexate in fibrosing
alveolitis associated with connective tissue disease. Thorax.
33. • Steen VD. Clinical manifestations of systemic sclerosis. Semin
Cutan Med Surg. 1998;17:48–54. A comprehensive review of the
general clinical features of systemic sclerosis.
34. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E,
Carpentier P, et al. The three-year incidence of pulmonary
arterial hypertension associated with systemic sclerosis in a
multicenter nationwide longitudinal study in France. Arthritis
35. • Reveille JD, Solomon DH. Evidence-based guidelines for the
use of immunologic tests: anticentromere, Scl-70, and nucleolar
antibodies. Arthritis Rheum. 2003;49:399–412. This article is
part of a series on immunologic testing guidelines published by
the American College of Rheumatology and HOC Committee on
Immunologic Testin. For further details an introduction to this
series has been published in Arthritis Care and Research, Vol 47,
Nr 4, August 2002 pp 429 –433.
36. Bouros D, Wells AU, Nicholson AG, Cobly TV, Polychronopou-
los V, Pantelidis P, et al. Histopathologic subsets of fibrosing
alveolitis in patients with systemic sclerosis and their relationship
to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.
37. Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ,
Maher TM, et al. Interstitial lung disease in systemic sclerosis:
a simple staging system. Am J Respir Crit Care Med.
38. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D,
Koch KM, et al. Intravenous pulse administration of cyclophos-
phamide versus daily oral treatment in patients with antineutro-
phil cytoplasmic antibody-associated vasculitis and renal
involvement: a prospective, randomized study. Arthritis Rheum.
39. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver
RM, et al. Effects of 1-year treatment with cyclophosphamide on
outcomes at 2 years in scleroderma lung disease. Am J Respir
Crit Care Med. 2007;176:1026–34.
40. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of
two parts). N Engl J Med. 1975;292:344–7.
41. • Bohan A, Peter JB. Polymyositis and dermatomyositis (second
of two parts). N Engl J Med. 1975;292:403–7. Original descrip-
tion and diagnostic criteria for polymyositis and dermatomyositis
by Bohan and Peter.
42. Krain L. Dermatomyositis in six patients without initial muscle
involvement. Arch Dermatol. 1975;111:241–5.
43. • Fathi M, Lundberg IE, Tornling G. Pulmonary complications of
polymyositis and dermatomyositis. Semin Respir Crit Care Med.
2007;28:451–8. A comprehensive review of polymyositis and der-
matomyositis with emphasis on the pulmonary manifestation.
44. • Ikezoe J, Johkoh T, Kohno N, et al. High-resolution CT findings
of lung disease in patients with polymyositis and dermatomyosi-
tis. J Thorac Imag. 1996;11:250–9. A review of radiological
features on chest HRCT in PM/DM.
45. Schwarz MI. The lung in polymyositis. Clin Chest Med.
46. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J,
Kitaichi M, et al. Two distinct clinical types of interstitial lung
disease associated with polymyositis/dermatomyositis. Respir
47. Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois
RM, et al. Variations in histological patterns of interstitial pneu-
monia between connective tissue disorders and their relationship
to prognosis. Histopathology. 2004;44:585–96.
230Curr Respir Care Rep (2012) 1:224–232
48. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, Cadranel J,
Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyo-
pathic dermatomyositis, dermatomyositis and polymyositis. Eur
Respir J. 2003;22:245–50.
49. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker
PA, Schroeder DR, et al. Polymyositis-dermatomyositis-
associated interstitial lung disease. Am J Respir Crit Care Med.
50. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Inter-
stitial lung disease in polymyositis and dermatomyositis: clinical
course and response to treatment. Semin Arthritis Rheum.
51. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease
with autoantibodies against aminoacyl tRNA synthetases in the
absence of clinically apparent myositis. Semin Arthritis Rheum.
52. Chen I, Jan Wu Y, Lin C, Fan K, Luo S, Ho H. Interstitial lung
disease in polymyositis and dermatomyositis. Clin Rheumatol.
53. • Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis.
Lancet. 2003;362:971–82. A comprehensive review of the general
clinical features of polymyositis and dermatomyositis.
54. Evans J. Antinuclear antibody testing in systemic autoimmune
disease. Clin Chest Med. 1998;19:613–25. vii.
55. Targoff IN. Humoral immunity in polymyositis/dermatomyositis.
J Invest Dermatol. 1993;100:116S–23.
56. Marie I, Hachulla E, Chérin P, Dominique S, Hatron P, Hellot M,
et al. Interstitial lung disease in polymyositis and dermatomyosi-
tis. Arthritis Rheum. 2002;47:614–22.
57. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U,
Devulder B. Pulmonary involvement in polymyositis and in
dermatomyositis. J Rheumatol. 1998;25:1336–43.
58. Selva-O’Callaghan A, Labrador-Horrillo M, Muñoz-Gall X,
Martínez-Gomez X, Majó-Masferrer J, Solans-Laque R, et al.
Polymyositis/dermatomyositis associated lung disease: analysis
of a series of 81 patients. Lupus. 2005;14:534–42.
59. Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Chérin P.
Antisynthetase syndrome. Joint Bone Spine. 2003;70:161–8.
60. Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka
R, Ito T, Nureki S, Kumamoto T. Successful treatment with tacro-
limus of progressive interstitial pneumonia associated with amyo-
pathic dermatomyositis refractory to cyclosporine. Clin Rheumatol.
61. Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T,
Miyasaka N. Favorable outcomes with tacrolimus in two
patients with refractory interstitial lung disease associated
with polymyositis/dermatomyositis. Clin Exp Rheumatol.
62. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K,
Matsuoka S, Kurihara Y, Osada H, Satoh M, Ozaki S. Intravenous
cyclophosphamide therapy for progressive interstitial pneumonia
in patients with polymyositis/dermatomyositis. Rheumatology
63. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H,
Tokuhira M, Amano K, Takeuchi T. Combination therapy with
corticosteroids, cyclosporin A, and intravenous pulse cyclophos-
phamide for acute/subacute interstitial pneumonia in patients
with dermatomyositis. J Rheumatol. 2005;32(9):1719.
64. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of
the anti-synthetase syndrome: a retrospective case series. Rheu-
matology (Oxford). 2009;48:968–71.
65. Lambotte O, Kotb R, Maigne G, Blanc F, Goujard C, Delfraissy
JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol.
66. Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H,
Suda T, Chida K. Intravenous immunoglobulin therapy for
refractory interstitial lung disease associated with polymyositis/
dermatomyositis. Lung. 2009;187(3):201.
67. Sjögren H. Zur Kenntnis der keratoconjunctivitis sicca. Acta
Ophthalomol. 1933;11(suppl II):1.
68. • Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM,
Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s
syndrome: a revised version of the European criteria proposed by
the American –European Consensus Group. Ann Rheum Dis.
2002;61:554–8. Diagnostic criteria for primary and secondary
Sjögren’s syndrome following revision by the European Study
Group on Classification Criteria for Sjögren’s syndrome.
69. Alexander EL, Provost TT, Stevens MB, Alexander GE. Neuro-
logic complications of primary Sjögren’s syndrome. Medicine
70. Carine S, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-
Richard C, Mariette X. Anticentromere antibodies identify
patients with Sjögren’s syndrome and autoimmune overlap syn-
drome. J Rheumatol. 2007;34:2253–8.
71. Fischbach M, Char D, Christensen M, et al. Immune complexes
in Sjögren’s syndrome. Arthritis Rheum. 1980;23:791–5.
72. • Fox R. Sjögren’s syndrome. Lancet. 2005;366:321–31. A
comprehensive review of the general clinical features of
73. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM,
Soussi T, et al. Lymphomas in patients with Sjögren’s syndrome
are marginal zone B-cell neoplasms, arise in diverse extranodal
and nodal sites, and are not associated with viruses. Blood.
74. Papathanasiou MP, Constantopoulos SH, Tsampoulas C, Drosos
AA, Moutsopoulos HM. Reappraisal of respiratory abnormalities
in primary and secondary Sjögren’s syndrome. A controlled
study. Chest. 1986;90:370–4.
75. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del
Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical
and immunologic expression in 1010 patients. Medicine
76. Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM.
Respiratory manifestations in primary Sjögren’s syndrome. A
clinical, functional, and histologic study. Chest. 1985;88:226–9.
77. • Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of
Sjögren’s syndrome. Clin Chest Med. 1998;19:687–99. viii. A
comprehensive review of the pleuro-pulmonary manifestations
78. Launay D, Hachulla E, Hatron P, Jais X, Simonneau G, Humbert
M. Pulmonary arterial hypertension: a rare complication of pri-
mary Sjögren syndrome: report of 9 new cases and review of the
literature. Medicine (Baltimore). 2007;86:299–315.
79. Chen H, Lai S, Kwang W, Liu J, Chen C, Huang D. Middle lobe
syndrome as the pulmonary manifestation of primary Sjögren’s
syndrome. Med J Aust. 2006;184:294–5.
80. Tavoni A, Vitali C, Cirigliano G, Frigelli S, Stampacchia G,
Bombardieri S. Shrinking lung in primary Sjögren’s syndrome.
Arthritis Rheum. 1999;42:2249–50.
81. • Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH.
Interstitial lung disease in primary Sjögren syndrome. Chest.
2006;130:1489–95. A comprehensive overview of interstitial lung
diseases in SjS.
82. Yamadori I, Fujita J, Bandoh S, Tokuda M, Tanimoto Y, Kataoka
M, et al. Nonspecific interstitial pneumonia as pulmonary in-
volvement of primary Sjögren’s syndrome. Rheumatol Int.
83. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM,
Harrison NK, et al. Interstitial lung disease guideline: the British
Thoracic Society in collaboration with the Thoracic Society of
Australia and New Zealand and the Irish Thoracic Society. Tho-
rax. 2008;63 Suppl 5:v1–58.
Curr Respir Care Rep (2012) 1:224–232 231
84. Devaraj A, Wells AU, Hansell DM. Computed tomographic Download full-text
imaging in connective tissue diseases. Semin Respir Crit Care
85. Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T,
Tomiyama N, et al. Pulmonary involvement in primary Sjög-
ren’s syndrome: spectrum of pulmonary abnormalities and
computed tomography findings in 60 patients. J Thorac Im-
86. • Honda O, Johkoh T, Ichikado K, Tomiyama N, Maeda M,
Mihara N, et al. Differential diagnosis of lymphocytic interstitial
pneumonia and malignant lymphoma on high-resolution CT. AJR
Am J Roentgenol. 1999;173:71–4. An interesting study compar-
ing HRCT-findings of lymphocytic interstitial pneumonia and
malignant lymphoma of the chest to delineate the differentiating
features of these two disorders.
87. Cervera R, Khamashta MA, Hughes GR. “Overlap” syndromes.
Ann Rheum Dis. 1990;49(11):947.
88. • Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undiffer-
entiated connective tissue diseases (UCTD). Autoimmun Rev.
2006;6(1):1. Description of “undifferentiated connective tissue
diseases” as a distinct disease entity.
89. • Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed
connective tissue disease—an apparently distinct rheumatic dis-
ease syndrome associated with a specific antibody to an extract-
able nuclear antigen (ENA). Am J Med. 1972;52(2):148.
Original description of “mixed connective tissue disease” as a
separate disease entity by Sharp et al.
al. Evaluation of interstitial lung disease in mixed connective tissue
disease (MCTD). Rheumatology (Oxford). 2005;44:656–61.
91. • Prakash UB. Respiratory complications in mixed connective
tissue disease. Clin Chest Med. 1998;19:733–46. ix. A compre-
hensive review of MCTD-related pulmonary complications.
92. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA,
Maltby JD, et al. A prospective evaluation emphasizing pulmo-
nary involvement in patients with mixed connective tissue dis-
ease. Medicine (Baltimore). 1984;63:92–107.
93. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM.
Prevalence of adult systemic lupus erythematosus in California
and Pennsylvania in 2000: estimates obtained using hospitaliza-
tion data. Arthritis Rheum. 2007;56:2092–4.
94. Swaak AJ, Nossent JC, Smeenk RJ. Systemic lupus erythemato-
sus. Int J Clin Lab Res. 1992;22:190–5.
95. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla
P, et al. Systemic lupus erythematosus: clinical and immunologic
patterns of disease expression in a cohort of 1,000 patients. The
European Working Party on Systemic Lupus Erythematosus.
Medicine (Baltimore). 1993;72:113–24.
96. • Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield
NF, et al. The 1982 revised criteria for the classification
of systemic lupus erythematosus. Arthritis Rheum. 1982;25:
1271–7. Revised Criteria for the diagnosis of SLE from the
Subcommittee for Systemic Lupus Erythematosus Criteria of the
American Rheumatism Association Diagnostic and Therapeutic
97. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution
chest CT in systemic lupus erythematosus. AJR Am J Roent-
98. • Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory
manifestations of systemic lupus erythematosus: old and new
concepts. Best Pract Res Clin Rheumatol. 2009;23:469–80. Con-
cise review of the pulmonary manifestations in SLE.
99. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla
P, et al. Morbidity and mortality in systemic lupus erythematosus
during a 5-year period. A multicenter prospective study of 1,000
patients. European Working Party on Systemic Lupus Erythema-
tosus. Medicine (Baltimore). 1999;78:167–75.
100. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is
valid, and renal and pulmonary organ scores are predictors of
severe outcome in patients with systemic lupus erythematosus. Br
J Rheumatol. 1996;35:248–54.
101. Bankier AA, Kiener HP, Wiesmayr MN, Fleischmann D,
Kontrus M, Herold CJ, et al. Discrete lung involvement
in systemic lupus erythematosus: CT assessment. Radiology.
102. Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmo-
nary abnormalities in patients with systemic lupus erythematosus:
assessment with high resolution computed tomography, chest
radiography and pulmonary function tests. Clin Exp Rheumatol.
103. Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC,
Sahn SA, et al. Pulmonary manifestations of systemic lupus
erythematosus: review of twelve cases of acute lupus pneumoni-
tis. Medicine (Baltimore). 1975;54:397–409.
104. Colby TV. Pulmonary pathology in patients with systemic auto-
immune diseases. Clin Chest Med. 1998;19:587–612. vii.
105. Min JK, Hong YS, Park SH, Park JH, Lee SH, Lee YS, et al.
Bronchiolitis obliterans organizing pneumonia as an initial man-
ifestation in patients with systemic lupus erythematosus. J Rheu-
106. Filipek MS, Thompson ME, Wang P, Gosselin MV, Primack LS.
Lymphocytic interstitial pneumonitis in a patient with systemic
lupus erythematosus: radiographic and high-resolution CT find-
ings. J Thorac Imaging. 2004;19:200–3.
107. Carette S, Macher AM, Nussbaum A, Plotz PH. Severe, acute
pulmonary disease in patients with systemic lupus erythematosus:
ten years of experience at the National Institutes of Health. Semin
Arthritis Rheum. 1984;14:52–9.
108. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar
hemorrhage and systemic lupus erythematosus. Clinical presen-
tation, histology, survival, and outcome. Medicine (Baltimore).
109. Todd DJ, Costenbader KH. Dyspnoea in a young woman with
active systemic lupus erythematosus. Lupus. 2009;18:777–84.
232Curr Respir Care Rep (2012) 1:224–232